Reglan Tardive Dyskinesia Settlement: Understanding Lawsuit Criteria

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Targeted Exposure Risk

The legacy of general health and science information has long served as a foundational resource for public awareness, covering topics from nutrition to preventive care without delving into specific clinical or occupational nuances. Such a framework provided a baseline understanding of health risks, but it often remained at a population-wide level, leaving room for more targeted inquiries. As we pivot from this general context, a natural bridge emerges toward occupational exposure concerns. In industrial settings, particularly those involving mass production, workers may encounter substances that warrant closer scrutiny. One such example is the transition from general health discussions to the specific risk associated with Reglan exposure. Reglan, a medication historically prescribed for gastrointestinal issues, has been linked to tardive dyskinesia—a movement disorder that can arise from prolonged use. This concern becomes especially relevant in occupational health, where employees might be exposed to the drug through manufacturing processes or workplace environments. The shift from broad health information to focused exposure risk underscores the need for precise criteria in legal contexts, such as the Reglan Tardive Dyskinesia lawsuit settlement criteria, which aim to address claims arising from such occupational or therapeutic exposures.

The Medical Link Between Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly used to treat nausea, vomiting, and gastroparesis (https://pubmed.ncbi.nlm.nih.gov/34712535/). Due to its mechanism of action, metoclopramide can lead to extrapyramidal side effects such as tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). Tardive dyskinesia is an often disabling hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents (https://pubmed.ncbi.nlm.nih.gov/29433808/). Although initially thought to most commonly occur with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Increased prescribing of these agents as well as low rates of remission have contributed to a rising prevalence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). The clinical presentation of tardive dyskinesia involves a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide, including Reglan, may also suppress, or partially suppress, the signs of TD, and may delay the diagnosis of TD because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis of TD requires differentiation from other movement disorders, and risk factors for TD include prior exposure to dopamine receptor blocking agents (https://pubmed.ncbi.nlm.nih.gov/34712535/).

Mechanism, Risk Factors, and Duration of Exposure

The mechanistic pathway linking Reglan to tardive dyskinesia involves its action as a dopamine D2-receptor blocking agent (https://pubmed.ncbi.nlm.nih.gov/34712535/). This blockade can lead to extrapyramidal side effects such as TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). The risk of developing TD increases with duration of metoclopramide treatment and total cumulative metoclopramide dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, avoid a total duration of treatment with metoclopramide products, including Reglan tablets, for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If longer term use is unavoidable, routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, TD can occur even after a single dose administration of metoclopramide, as reported in a case of a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This case highlights that the timeline between exposure and documented harm can be short, though the occurrence is somewhat rare (https://pubmed.ncbi.nlm.nih.gov/34712535/).

Adequacy of Warnings and Settlement Considerations

The adequacy of warnings regarding Reglan and tardive dyskinesia is addressed in the prescribing information. The boxed warning states that metoclopramide, including Reglan, can cause tardive dyskinesia, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning emphasizes that the risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information advises using Reglan for the shortest duration of treatment and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also instructs to immediately discontinue Reglan in patients who develop signs or symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, the warnings and precautions section notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD continue to occur, and settlement-related considerations for affected patients may involve evaluating whether the warnings were adequate and whether the patient was informed of the risks. Settlement-related considerations for affected patients include the timeline between exposure and documented harm, the duration and dosage of Reglan treatment, and whether the patient had risk factors for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, TD can occur even after short-term use, as seen in the case of a single dose administration (https://pubmed.ncbi.nlm.nih.gov/34712535/). Patients who develop TD may seek legal recourse, and settlement criteria often involve demonstrating that the drug caused the condition and that the warnings were insufficient. The FDA-approved labeling includes a boxed warning, but some patients may argue that the risks were not adequately communicated. The availability of VMAT2 inhibitors for the treatment of TD, such as tetrabenazine and its derivatives, provides therapeutic options but does not reverse the condition (https://pubmed.ncbi.nlm.nih.gov/29433808/). These treatments can help manage symptoms but are not curative.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Reglan and tardive dyskinesia?

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses, but TD can occur even after short-term use (https://pubmed.ncbi.nlm.nih.gov/34712535/).

What are the settlement criteria for a Reglan tardive dyskinesia lawsuit?

Settlement criteria typically require documented Reglan exposure and a confirmed TD diagnosis. Key factors include the duration and dosage of Reglan treatment, the timeline between exposure and harm, and whether the warnings were adequate. Patients must demonstrate that Reglan caused TD and that the risks were not properly communicated (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.